Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Commentary|Articles|May 6, 2026
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Preparations for the
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Advertisement
Advertisement